Jefferies puts Cerep on hold

Cerep SA was given a hold rating by Jefferies & Co., Inc. analyst Robin Campbell. The analyst believes the acquisition of Touchstone Research for $10 million by Cerep's subsidiary Hesperion helps strengthen Cerep's U.S. cardiology franchise. However, Jefferies will be looking at the company's growth outlook for both drug discovery and clinical services. Shares of the Paris-based pharmaceutical company were up €0.49, or 6.54%, at €7.98 on volume of 59,380 shares versus the three-month running average of 17,489 shares. (Paris: CER)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.